PMN Latest Press Releases

-- November 12, 2026 --

ProMIS Neurosciences Announces Third Quarter 2026 Financial Results and Reaffirms First Quarter 2027 Topline Data Timing Globe Newswire 4:05 PM

-- November 5, 2026 --

ProMIS Neurosciences to Participate in Upcoming Conferences in November Globe Newswire 7:00 AM

-- November 3, 2026 --

ProMIS Neurosciences to Report Third Quarter 2026 Financial Results and Business Update on November 12, 2026 Globe Newswire 7:00 AM

-- October 6, 2026 --

ProMIS Neurosciences Appoints Seasoned Alzheimer's and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer Globe Newswire 7:05 AM

-- September 1, 2026 --

ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September Globe Newswire 8:00 AM

-- August 13, 2026 --

ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights Globe Newswire 4:00 PM

-- August 3, 2026 --

ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026 Globe Newswire 4:00 PM

-- July 28, 2026 --

ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer's Disease Trial Globe Newswire 6:00 AM

-- July 27, 2026 --

ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer's Disease Globe Newswire 4:00 PM

-- July 14, 2026 --

ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026 Globe Newswire 2:30 AM

Market Data Delayed 15 Minutes